Emergent Biosolutions
EBS
195 hedge funds and large institutions have $374M invested in Emergent Biosolutions in 2026 Q2 according to their latest regulatory filings, with 33 funds opening new positions, 68 increasing their positions, 63 reducing their positions, and 26 closing their positions.
303% more call options, than puts
Call options by funds: $5.51M | Put options by funds: $1.37M
27% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 26
3% more funds holding
Funds holding: 190 → 195 (+5)
2.31% more ownership
Funds ownership: 84.11% → 86.42% (+2.3%)
8% more repeat investments, than reductions
Existing positions increased: 68 | Existing positions reduced: 63
4% more capital invested
Capital invested by funds: $361M → $374M (+$13M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LSV Asset Management
Chicago,
Illinois
|
+$6.69M |
| 2 |
AA
Ancora Advisors
Cleveland,
Ohio
|
+$5.51M |
| 3 |
Millennium Management
New York
|
+$4.52M |
| 4 |
Russell Investments Group
London,
United Kingdom
|
+$4.38M |
| 5 |
BlackRock
New York
|
+$3.14M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
Palisade Capital Management
Fort Lee,
New Jersey
|
-$5.74M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$4.8M |
| 3 |
Pacer Advisors
Malvern,
Pennsylvania
|
-$3.48M |
| 4 |
BNP Paribas Financial Markets
Paris,
France
|
-$2.9M |
| 5 |
Charles Schwab
San Francisco,
California
|
-$2.55M |
EBS Hedge Fund Activity: Q2 2026 in Review
195 of the 8,305 institutional investors tracked by Wall St. Rank reported a position in Emergent Biosolutions (EBS) for Q2 2026, worth a combined $374M — up 3.6% from $361M a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new EBS positions and 26 closed out — a net gain of 7 holders — while 68 added to existing stakes and 63 trimmed.
The largest buyer was LSV Asset Management, adding an estimated $6.69M. The largest seller was Palisade Capital Management, cutting an estimated $5.74M.
- 195 institutional investors held Emergent Biosolutions (EBS) as of Q2 2026, up from 190 in Q1 2026.
- Funds reported $374M of Emergent Biosolutions stock for Q2 2026, up 3.6% quarter-over-quarter.
- 33 funds opened new Emergent Biosolutions positions in Q2 2026 and 26 closed out, a net change of +7 holders.
- The largest Emergent Biosolutions buyer in Q2 2026 was LSV Asset Management, an estimated $6.69M added.
- The largest Emergent Biosolutions seller in Q2 2026 was Palisade Capital Management, an estimated $5.74M sold.
Based on aggregated 13F filings for Q2 2026.